In the intention-to-treat (ITT) population, the median Progression-Free Survival (PFS) was 4.1 months in the SIR-Spheres® Y-90 resin microspheres arm vs. 3.7 months in the sorafenib arm (HR: 1.03 [95% CI: 0.85-1.25]; p=0.76).

Reprinted from The Lancet Oncology, Vol. 18, Vilgrain V, Pereira H, Assenat E et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Pages 1624-1636., Copyright (2017), with permission from Elsevier.

Vilgrain V et al.  Lancet Oncol 2017; 18: 1624–36.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage